Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon

Tala Ballouz1, Rony M Zeenny2, Nisrine Haddad2, Nesrine Rizk1, Souha S Kanj1

1 Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 Department of Pharmacy, American University of Beirut Medical Center, Beirut, Lebanon

Abstract
Introduction: Fosfomycin has re-emerged as a possible therapeutic alternative for the treatment of resistant bacterial pathogens. Its main mechanism of action is the inhibition of the initial step of cell wall synthesis and is active against both Gram-positive and Gram-negative bacteria. However, its clinical effectiveness against multidrug resistant bacteria remains largely unknown. Therefore, we aim to evaluate the clinical and microbiological effectiveness of intravenous fosfomycin as well as its safety in a tertiary care teaching hospital in Lebanon.

Methodology: This is a retrospective chart review of adult patients who had presented to the hospital and were treated with intravenous fosfomycin for at least 24 hours for any type of infection between 2014 and 2019.

Results: Among 31 episodes treated with intravenous fosfomycin, 68% had an overall favorable clinical response. In 84% of the episodes, fosfomycin was administered in combination with other antibiotics, commonly tigecycline. Of those with available cultures at end of therapy, 73% achieved microbiological success. No relapse was documented within 30 days of completion of therapy. In the episodes secondary to resistant pathogens, the rates of favorable clinical outcome and microbiological success at the end of therapy were 71% and 73%, respectively. Fosfomycin resistance developed in two cases and mild adverse events occurred in 65% of the episodes during the course of treatment.

Conclusions: Fosfomycin is a safe and effective option in the treatment of multi-drug resistant infections. Nevertheless, careful stewardship is important to maintain its efficacy and to reduce the risk of selection of antimicrobial resistance.

Key words: Antimicrobials; Fosfomycin; Lebanon; Middle East; resistance; E-coli.

J Infect Dev Ctries 2021; 15(9):1308-1313. doi:10.3855/jidc.14125

Introduction
Antimicrobial resistance (AMR) is a major public health issue worldwide, threatening our ability to adequately prevent and treat infections [1–3]. With very few antimicrobials available in the pipeline, a prominent strategy in managing resistant bacteria is repurposing of older antibiotics, such as Fosfomycin [4]. Fosfomycin is a bactericidal antibiotic active against a wide range of Gram-positive and Gram-negative bacteria [5,6]. Specifically, it was found to be highly active against Staphylococcus aureus and Enterococcus spp and exhibits considerable activity against Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamases (ESBL) - and carbapenemase producers [7]. Currently, only oral formulations of fosfomycin are approved for treating uncomplicated urinary tract infections (UTIs). However, intravenous (IV) fosfomycin has re-emerged as a potential treatment for various infections like UTIs, pneumonias, and skin and soft tissue infections (SSTIs) with overall cure rates over 80% [6,8–10]. It is generally used as part of a combination regimen when first-line agents have failed to demonstrate efficacy [11]. Few clinical trials have assessed the effectiveness of IV fosfomycin [11]. In a recent phase 2 randomized trial, Kaye et al. reported non-inferiority of IV fosfomycin to piperacillin-tazobactam for treatment of complicated UTI, with a high cure rate and tolerability [12]. In an effort to further describe the role of IV fosfomycin in treating multi-drug resistant (MDR) infections, we aimed at evaluating the clinical and microbiological effectiveness of IV fosfomycin and its safety profile in a tertiary care center in Lebanon.

Methodology
This is a retrospective study conducted at the American University of Beirut Medical Center (AUBMC), a tertiary care center in Beirut, Lebanon. We included all adult patients (≥ 18 years) who were...
treated with IV fosfomycin for at least 24 hours for any type of infection between January 2014 and June 2019. This study was approved by the Institutional Review Board of the American University of Beirut (IRB_BIO-2019-0203). The requirement for informed consent was waived because of the retrospective nature of the study.

A standardized spreadsheet was used to collect information on patients’ demographics, clinical characteristics (e.g. comorbidities, infection requiring IV fosfomycin), data related to the use of fosfomycin (e.g. empirical versus targeted use, dose, side effects) and outcomes. Fosfomycin dose and duration were determined by the treating infectious diseases physician based on the type and severity of the infection. MDR was defined as non-susceptibility to at least one agent in three or more antimicrobial categories. Extensive-drug resistance (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer categories [13]. Susceptibility of Enterobacteriales to fosfomycin was interpreted using Clinical and Laboratory Standards Institute (CLSI) cut-off points [14]. Cut-off points for Acinetobacter baumannii and Pseudomonas aeruginosa are not determined.

Primary outcome was clinical response at end of therapy (EOT). Patients were determined to have a favorable clinical response if they achieved complete clinical success with resolution of signs/symptoms of infection, or if they had clinical improvement but additional treatment was required for reasons not related to the primary infection. Otherwise, patients were determined to have clinical failure.

Table 1. Patient Demographics.

| Variable (N = 28) | N (%) |
|------------------|-------|
| Age, mean (SD)   | 56.43 (17.66) |
| Gender: Male, N (%) | 20 (71) |
| Comorbidities    |       |
| Hypertension     | 9 (32) |
| Dyslipidemia     | 7 (25) |
| Diabetes mellitus| 5 (18) |
| Coronary artery disease | 3 (11) |
| Chronic kidney disease | 1 (4) |
| Chronic obstructive pulmonary disease | 1 (4) |
| Liver disease    | 1 (4) |
| Malignancy       | 13 (46) |
| Hematologic      |       |
| Acute myeloid leukemia | 4 (14) |
| Acute lymphoblastic leukemia | 1 (4) |
| Diffuse large B cell lymphoma | 2 (7) |
| T cell lymphoma  | 1 (4) |
| Hodgkin Lymphoma | 1 (4) |
| Oncologic        |       |
| Colorectal cancer | 4 (14) |
| Squamous cell cancer of the mandible | 1 (4) |
| Bladder cancer   | 1 (4) |

N: number; SD: standard deviation.

Secondary outcomes included microbiological response, development of fosfomycin resistance, adverse events including Clostridium difficile infection, and mortality (all-cause and attributable). In those with available follow-up cultures, microbiological response was determined at 72 hours and EOT. Microbiological success was achieved in case of sterile follow-up cultures during or after the course of IV fosfomycin. In case of polymicrobial infections, response was based on the primary site of infection. Relapse was defined as recurrent infection with the same initial organism after a bacterial response to IV fosfomycin within 30 days of EOT. Reinfection was defined as recurrence of infection within 30 days of EOT due to an organism distinct from that isolated before therapy. Attributable mortality was defined as death occurring during or within 30 days of hospitalization related to the infection for which fosfomycin was administered and with no other causes identified.

Descriptive statistics were used. Continuous variables were presented by mean values and standard deviations (SD) if normally distributed and as median and interquartile ranges (IQR) if not. Categorical variables were presented by numbers and percentages.

Results

Characteristics of the population

In total, 41 patients received IV fosfomycin during the study period, of which 13 were excluded: six patients were younger than 18 years, six received fosfomycin for less than 24 hours and one patient was still admitted at the time of data collection. We included 28 patients with 31 admissions: two patients received IV fosfomycin more than once. Patients were predominantly male (71%) with a mean age of 56.43 years (±17.66). The majority of patients (27/28) had at least one comorbidity with hypertension being the most common (32%) (Table 1).

Infection and treatment characteristics

Prior to the infection, patients had been hospitalized for a median duration of 7 days (IQR 0-18). Fosfomycin was used to treat blood-stream infection (BSI) (64%), UTI (16%), pneumonia (10%) and febrile neutropenia (10%). Administration of fosfomycin was mostly guided by culture results (77%). It was given empirically in seven cases due to history of carbapenem-resistant Enterobacteriaceae (CRE) (n = 5) and as salvage therapy (n = 2).

A total of 30 organisms were identified in 28/31 clinical episodes. All were Gram-negative bacteria and 93% of episodes were monomicrobial. Figure 1 shows
the distribution of the isolated organisms with 54% being Enterobacterales. 14/30 of the strains were MDR and 14/30 were XDR. 78% of Acinetobacter baumannii and 50% of Pseudomonas aeruginosa and Enterobacter sp. were XDR (Figure 2).

Fosfomycin was started within a mean of 5.11 days (±2.63) from the date of cultures. Fosfomycin dose and duration were determined by the treating infectious diseases physician based on the type and severity of the infection. In those with normal creatinine clearance, the usual dosing regimen ranges from 12-16 grams per day, administered in 2-4 divided doses. Higher daily doses (up to 24 grams) were used in severe infections. Mean daily fosfomycin dose was 13.17 grams (±5.60) for a median duration of 8 days (IQR 6-15). Fosfomycin was administered almost always (n=26) in combination with other antibiotics, mostly tigecycline (n=8) and amikacin (n=3), based on sensitivities. Patients with BSI and pneumonia received fosfomycin for an average duration of 11.5 and 10 days, respectively; whereas those with UTI and febrile neutropenia with no focus received it for an average of 6 and 7 days, respectively. Fosfomycin treatment was completed in 21/31 cases. Three patients died while on treatment and in the remaining cases, fosfomycin was not completed due to change in therapy, side effects, or development of resistance.

**Clinical Outcome**

Among 31 episodes treated with IV fosfomycin, 21 (68%) cases had an overall favorable clinical response and 14 cases (45%) reached complete clinical success at EOT. In those clinically failing, eight had persistent infections, one of which was due to the development of fosfomycin resistance in a carbapenem resistant E. coli. When assessed by the site of infection, 100%, 80% and 65% of pneumonia, UTIIs and bacteremia, respectively, had a favorable clinical response. 67% of the cases without a documented infectious focus had clinical failure. A favorable outcome was achieved in 82% of infections caused by Enterobacterales and 75% of those caused by Pseudomonas aeruginosa. In infections due to Acinetobacter baumannii, a favorable outcome was seen in 56% of cases. Overall in-hospital mortality was 26% and attributable mortality was 13%.

**Microbiologic Outcome**

Overall, there were 21 episodes with follow-up cultures at least once during or after EOT (Table 2).

At 72 hours of treatment, microbiological eradication occurred in 9/9 episodes. Subsequent

**Table 2. Microbiological outcome in patients by type of infection and microbiology.**

| Variable, N (%) | Microbiological eradication |
|----------------|-----------------------------|
|                | At 72 hours                | At end of therapy |
| All patients   | 9/9 (100)                  | 8/11 (73)         |
| Blood stream infections | 7/7 (100)          | 5/6 (83)         |
| Urinary tract infection | 1/1 (100)          | 3/3 (100)        |
| Pneumonia      | 1/1 (100)                  | 0/2 (0)          |
| **By organism**|                            |                  |
| Enterobacteriaceae | 6/6 (100)        | 6/7 (86)         |
| Acinetobacter baumannii | 2/2 (100)       | 3/3 (100)        |
| Pseudomonas aeruginosa | 1/1 (100)        | 0/2 (0)          |

N: number.
cultures at EOT were available in 11 episodes with 73% achieving microbiological success. 2/3 episodes where fosfomycin failed microbiologically were due to Pseudomonas aeruginosa. Within 30 days of EOT, none of the 10 patients with available follow-up data developed a relapse. However, 5/10 presented with a re-infection with Gram-negative bacteria.

In episodes secondary to MDR or XDR pathogens, rates of favorable clinical outcome and microbiological success at EOT were 71% and 73%, respectively.

Adverse events and fosfomycin resistance
Fosfomycin resistance developed in two patients, both of which received fosfomycin in combination with other antibiotics (amikacin and tigecycline). 26 mild adverse events occurred during treatment. The most frequent adverse event was hypokalemia (n=14) and hypernatremia (n=6), which were not present before the initiation of fosfomycin. Five patients developed diarrhea, four of which tested negative for C.difficile. One patient developed C.difficile infection within a month of fosfomycin treatment. All five patients were on at least one antibiotic other than fosfomycin. None developed pulmonary edema or hypertensive crises.

Discussion
In this study, we report favorable clinical and microbiological outcomes in patients treated with IV fosfomycin. Similar to the literature, our results show that fosfomycin can be a potentially reliable treatment option for infections caused by MDR Gram-negative bacteria [6,8–12,15–17].

Fosfomycin has been classically used in UTIs. However, use of IV fosfomycin beyond the urinary tract has gained more interest due to its unique mechanisms of action and favorable safety profile. Successful treatment of SSTI, BSI and pneumonias with IV fosfomycin has been documented [10,11,15–17]. In our study, IV fosfomycin was administered in a broad range of infections caused by Gram-negative bacteria with a favorable overall clinical response of 68%. We report high clinical success rates for pneumonias, BSI and UTI similar to those reported by Dinh et al. [17] but lower than those reported by Putensen et al. (81% overall and 85% in MDR infections) [16]. On the other hand, only 33% of those receiving fosfomycin for febrile neutropenia had a favorable clinical response. However, these patients received fosfomycin as a last resort empiric therapy, did not have a documented infectious focus and were markedly ill.

In those with a documented infection, Enterobacterales, namely E. coli, were the most common pathogens. 83% of the episodes caused by Enterobacterales had a favorable clinical response, compared to 75% for those caused by P. aeruginosa and 56% by A. baumannii. These results are in line with other studies. In fact, fosfomycin has demonstrated good in-vitro and clinical activity against E. coli and K. pneumoniae including ESBL and carbapenemase producers but is less active against MDR P.aeruginosa and A.baumannii [7,17–21].

Multiple guidelines and consensus on managing MDR infections have suggested fosfomycin as a relevant treatment option in combination with other antibiotics. Davido et al. reported that fosfomycin was the most prescribed last resort antibiotic in combination regimens [22]. This has been supported by in-vitro experiments where synergism was detected between fosfomycin and other antimicrobials such as meropenem in KPC-producing K. pneumoniae [18,23]. In our study, fosfomycin was used almost exclusively in combination, namely with tigecycline, which may have led to the favorable results. Furthermore, higher frequency of emerging resistance to fosfomycin has been documented when used as a single agent [11,24,25]. In contrast to most literature but similar to results by Karageorgoulos et al. [24], both cases in our study subsequently developing resistance had received fosfomycin as part of a combination therapy. Perhaps underdosing and persistent neutropenia explain the findings. In any case, clinicians need to be aware of the possibility of resistance development during the course of fosfomycin treatment.

All-cause and attributable mortality rates of our study population were around 25% and 13%, respectively. All those who died had a complicated stay and 88% of them had a hematological malignancy. Such a mortality rate may be expected in a severely ill and comorbid population and is within the range reported in the literature [26].

In regards to adverse effects, fosfomycin has been reported to be safe and well tolerated with electrolyte disturbances and gastrointestinal side effects being the most common [11,27]. At least one adverse event was recorded in 65% in our study. However, most patients were receiving other medications concomitantly and thus we cannot be certain that the adverse events were directly related to fosfomycin. Nevertheless, all were mild with hypokalemia and hypernatremia being the most frequent. This high frequency of electrolyte disturbances warrants careful monitoring of the fluid and electrolyte balance in patients receiving IV fosfomycin.
To our knowledge, this is the first study in the Middle East to assess the use of IV fosfomycin for resistant Gram-negative infections. However, our study has some limitations. It was a retrospective monocentric study; therefore, findings may not be applicable to other centers. The small sample size of our cohort did not allow any further analyses to identify differences between groups. Additionally, due to the retrospective nature of the study, important variables, such as timing of follow-up cultures, were not standardized. Larger comparative cohorts are warranted to analyze prescription patterns and outcomes.

Conclusions
Our results suggest that fosfomycin is a safe and effective option for the treatment of MDR organisms. This value appears to be the strongest for E. coli infections of various sites. However, stewardship with prudent use of antibiotics and monitoring of susceptibility patterns is important to reduce the risk of selection of AMR, if we are to keep this agent in our treatment armamentarium.

References
1. World Health Organization (2014) Antimicrobial resistance. Global Report on Surveillance. Geneva: World Health Organization.
2. Centers for Disease Control and Prevention (2019) Antibiotic Resistance Threats in the United States, 2019. Available: www.cdc.gov/DrugResistance/Biggest-Threats.html. Accessed 4 February 2020.
3. World Health Organization (2015) Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization.
4. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL (2012) “Old” antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25: 626–33.
5. Barry AL, Brown SD (1995) Antibacterial spectrum of fosfomycin trometamol. J Antimicrob Chemother 35: 228–30.
6. Dijkmans AC, Zacarias NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerling IMC (2017) Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics 6: 24.
7. Kaase M, Szabados F, Anders A, Gatermann SG (2014) Fosfomycin susceptibility in carbapenem-resistant enterobacteriaceae from Germany. J Clin Microbiol 52: 1893–7.
8. Schintler M V, Traunmu F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Scharnagl E, Joukhadar C (2009) High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 64: 574–8.
9. Pflauser B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C (2004) Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. 53: 848–52.
10. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafaëlidou PI (2008) Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections. Rev Anti-Infective Agents 46: 1069–77.
11. Graben B, Graninger W, Rodriguez Baño J, Dinh A, Liesenfeld DB (2017) Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 23: 363–72.
12. Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiu E, Das A, Skarinsky D, Eckburg PB, Ellis-Grosse EJ (2019) Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Int Infect Dis.
13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268–81.
14. Clinical and Laboratory Standards Institute (2020) M100. Performance standards for antimicrobial susceptibility testing. 30th edition. Available: http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI M100 ED30:2020&x=SPDF&src=BB. Accessed 4 February 2020.
15. Michalopoulos AS, Livadiatis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15: e732-9.
16. Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, Weiler N, Kindgen-Milles D, Jaschinski U, Weile J, Lindau S, Kieninger M, Falthauser A, Jung N, Teschendorf P, Adamzik M, Gründling M, Wahlers T, Gerlach H, Litty FA (2019) Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection 47: 827–36.
17. Dinh A, Salomon J, Bru JP, Bernard L (2012) Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 44: 182–9.
18. Sastry S, Clarke KG, Alrowais H, Querry AM, Shutt KA, Doi Y (2015) Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. Antimicrobial Agents Chemother 59: 7355–61.
19. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR (2011) Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrobial Agents Chemother 55: 4295–301.
20. Falagas ME, VouloumanouEK, Samonis G, Vardakas KZ (2016) Fosfomycin, Clin Microbiol News 29: 321–47.
21. Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ (2015) In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 70: 3042–50.
22. Davido B, Bouchand F, Dinh A, Perronne C, Villart M, Senard O, Salomon J (2017) Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study. Int J Antimicrob Agents 50: 142–7.
23. Samonis G, Maraki S, Karageorgopoulos DE, VouloumanouEK, Falagas ME (2012) Synergy of fosfomycin with carbenapens, colistine, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli.

J Infect Dev Ctries 2021; 15(9):1308-1313.

1312
and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31: 695–701.

24. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL (2012) Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 67: 2777–9.

25. Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, Ballestero-Tellez M, Rodriguez-Martinez JM, Conejo MC, Van Guider M, Rodriguez-Baño J, Pascual A, Hope WW (2015) Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother 59: 5602–10.

26. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiaris M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43: 52–9.

27. Iarikov D, Wassel R, Farley J, Nambiar S (2015) Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infect Dis Ther 4: 433–58.

Corresponding author
Souha S, Kanj, MD, FACP, FIDSA, FRCP, FESCMI, FECMM
Department of Internal Medicine, American University of Beirut Medical Center,
Cairo Street, Hamra, Beirut, Lebanon
PO Box 11-0236 Riad El Solh 1107 2020
Telephone: 00961-1-350000
Fax: 961-1-370814
Email: sk11@aub.edu.lb

Conflict of interests: No conflict of interests is declared.